Neoadjuvant PD-1–based immunotherapy plus chemotherapy produced pCRs across three cohorts in resectable locally advanced HNSCC.
Commentary|Articles|December 5, 2025
Experts Prepare for Several Key MCL Presentations at ASH 2025
Author(s)Caroline Seymour
Fact checked by: Chris Ryan
Hematology experts share the MCL abstracts they’re most looking forward to seeing at the 2025 ASH Annual Meeting.
Advertisement
Advertisement
Research breakthroughs in metabolic reprogramming–driven resistance and next-generation targeted inhibition in mantle cell lymphoma (MCL) are poised to take center stage at the
Related to this article
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
Sonrotoclax monotherapy produced durable responses in Chinese patients with relapsed/refractory mantle cell lymphoma.
Dostarlimab monotherapy produced a 27% response rate in PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma
Marc S. Hoffmann, MD, discusses data for sonrotoclax plus zanubrutinib and unmet needs in the mantle cell lymphoma treatment paradigm.
Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.
Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.
Obinutuzumab plus zanubrutinib produced high complete response rates with manageable toxicity in older patients with previously untreated mantle cell lymphoma.
Advertisement
Advertisement